Clopidogrel ratiopharm 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
N/0023 
Minor change in labelling or package leaflet not 
15/11/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0022 
C.I.2.a - Change in the SPC, Labelling or PL of a 
02/06/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/10/2021 
22/10/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0020 
C.I.2.a - Change in the SPC, Labelling or PL of a 
03/05/2021 
04/06/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0019/G 
This was an application for a group of variations. 
02/03/2021 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
IA/0018 
A.7 - Administrative change - Deletion of 
18/02/2021 
04/06/2021 
Annex II and 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
PL 
IB/0017 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/11/2020 
04/02/2021 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0016/G 
This was an application for a group of variations. 
21/02/2020 
04/02/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0014 
Renewal of the marketing authorisation. 
19/09/2019 
11/11/2019 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Clopidogrel ratiopharm in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IAIN/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
22/08/2019 
11/11/2019 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0012/G 
This was an application for a group of variations. 
31/05/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0013/G 
This was an application for a group of variations. 
28/05/2019 
11/11/2019 
SmPC, Annex 
II, Labelling 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0011 
B.II.b.5.z - Change to in-process tests or limits 
25/09/2018 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/04/2018 
12/11/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0009 
B.II.b.2.c.1 - Change to importer, batch release 
04/12/2017 
12/11/2018 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0008/G 
This was an application for a group of variations. 
21/09/2017 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0007/G 
This was an application for a group of variations. 
22/05/2017 
29/06/2017 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0006/G 
This was an application for a group of variations. 
06/03/2017 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0005/G 
This was an application for a group of variations. 
16/12/2016 
n/a 
B.II.e.1.a.1 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
B.II.e.1.a.1 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
IA/0004 
A.7 - Administrative change - Deletion of 
12/04/2016 
14/11/2016 
Annex II and 
manufacturing sites 
PL 
IB/0003/G 
This was an application for a group of variations. 
09/12/2015 
14/11/2016 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IAIN/0002 
B.II.b.2.c.1 - Change to importer, batch release 
27/11/2015 
14/11/2016 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0001 
Transfer of Marketing Authorisation 
07/07/2015 
31/07/2015 
SmPC, 
Labelling and 
PL 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
